Pila Pharma Feed

2026-03-18 18:15:00 PILA PHARMA POSTPONES THE PUBLICATION OF THE ANNUAL REPORT AND THE ANNUAL GENERAL MEETING

2026-03-05 16:15:00 PILA PHARMA: TO PARTICIPATE IN PHARMA PARTNERSHIP CONFERENCE BIO EUROPE SPRING IN LISBON, MARCH 23-25 1,25 SEK | -5,32% | 0,06 MSEK

2026-03-05 15:30:13 PILA PHARMA: TO2 WARRANTS CONVERTED, SHARES ARE NOW TRADABLE - CEO & FOUNDER'S PARTICIPATION DISCLOSED 1,25 SEK | -5,32% | 0,06 MSEK

2026-02-17 16:00:00 PILA PHARMA: MANAGEMENT TEAM COMMENTS ON OUTCOME OF TO2 WARRANTS 1,27 SEK | 0,00% | 0,30 MSEK

2026-02-17 12:00:00 PILA PHARMA ANNOUNCES THE OUTCOME IN THE EXERCISE OF WARRANTS OF SERIES TO2 1,27 SEK | 0,00% | 0,30 MSEK

2026-02-12 12:00:00 PILA PHARMA: Upcoming last days for exercise with the warrants of series TO2 1,12 SEK | -6,50% | 0,32 MSEK

2026-02-11 16:30:00 PILA PHARMA: CEO REPORT INTERVIEW AND Q&A ON CLINICAL PLANS, TO2 WARRANTS AND MORE, AVAILABLE FOR REPLAY NOW 1,20 SEK | -9,64% | 0,29 MSEK

2026-02-10 11:00:00 PILA PHARMA: INVITATION TO LIVE H2 / YEAR-END REPORT INTERVIEW AND Q&A TODAY AT 14:00 CET 1,33 SEK | -0,60% | 0,05 MSEK

2026-02-10 08:30:00 PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s year-end report for the period January - December 2025. 1,33 SEK | -0,60% | 0,05 MSEK

2026-02-09 15:00:00 PILA PHARMA PREPARES CLINICAL TRIAL APPLICATION IN RARE DISEASE ERYTHROMELALGIA 1,34 SEK | +10,78% | 0,17 MSEK

2026-02-05 08:45:00 THE EXERCISE PRICE FOR THE WARRANTS OF SERIES TO2 IN PILA PHARMA HAS BEEN DETERMINED TO SEK 1.50 AND THE EXERCISE PERIOD COMMENCES TODAY 1,19 SEK | +4,59% | 0,29 MSEK

2026-02-05 08:40:00 PILA PHARMA ACCELERATES THE PUBLICATION OF THE INTERIM REPORT OF THE SECOND HALF OF 2025 1,19 SEK | +4,59% | 0,29 MSEK

2026-01-27 08:55:00 PILA PHARMA: INVITATION TO LIVE Q&A TODAY, JANUARY 27, REGARDING PRECLINICAL STUDIES AND UPCOMING CLINICAL STUDIES 1,32 SEK | -9,22% | 1,36 MSEK

2026-01-26 11:00:00 PILA PHARMA SIGNS WITH NEW CLINICAL CRO TO PREPARE FOR CLINICAL PHASE IN OBESITY AFTER PRECLINICAL OBESITY STUDIES 1,45 SEK | -36,23% | 5,42 MSEK

2026-01-16 09:30:00 PILA PHARMA: CEO PARTICIPATED IN SWEDISH INVESTMENT PODCAST MARKET MAKERS 2,17 SEK | +3,33% | 0,76 MSEK

2026-01-16 08:30:00 PILA PHARMA: ANALYST GROUP INITIATES NEW EQUITY RESEARCH COVERAGE - BASE CASE TARGET OF SEK 6.30 2,17 SEK | +3,33% | 0,76 MSEK

2026-01-05 09:05:00 PILA PHARMA: INVITED TO PRESENT AT BIOTECH SHOWCASE / J.P MORGAN HEALTHCARE WEEK IN SAN FRANCISCO, JANUARY 13, 2026 1,96 SEK | -3,45% | 0,32 MSEK

2026-01-02 11:09:43 PILA PHARMA: CEO GUSTAV H. GRAM ACQUIRES ADDITIONAL SHARES 2,03 SEK | -1,46% | 0,46 MSEK

2025-12-19 08:45:00 PILA PHARMA: PRECLINICAL STUDIES OF XEN-D0501 IN OBESITY INITIATED 2,25 SEK | -2,17% | 0,37 MSEK

2025-12-04 16:00:00 PILA PHARMA ANNOUNCES PRE-CLINICAL OBESITY AND AMYLIN SPECIALIST PROFESSOR THOMAS LUTZ TO JOIN AS SCIENTIFIC ADVISER 2,12 SEK | -2,52% | 0,48 MSEK

2025-10-27 16:00:00 PILA PHARMA: UPCOMING PARTICIPATION IN OBESITYWEEK AND AMERICAN HEART ASSOCIATION CONVENTION 2,25 SEK | +1,12% | 0,17 MSEK

2025-10-07 11:45:00 PILA PHARMA: CEO GUSTAV H. GRAM ACQUIRES ADDITIONAL SHARES 2,43 SEK | +3,85% | 0,91 MSEK

2025-09-30 17:15:00 PILA PHARMA ENTERS INTO AGREEMENT WITH THE CRO GUBRA ON PRECLINICAL TRIALS OF XEN-D0501 IN OBESITY 2,13 SEK | -0,93% | 0,49 MSEK

2025-09-08 11:55:52 PILA PHARMA TO PARTICIPATE AT THE 61ST EASD DIABETES & OBESITY SCIENTIFIC MEETING, NEXT WEEK 16-19 SEPTEMBER IN VIENNA 2,24 SEK | -5,49% | 1,01 MSEK

2025-09-08 11:25:22 PILA PHARMA: ALL H1 REPORT & INVESTOR INTERVIEWS NOW ONLINE 2,24 SEK | -5,49% | 1,01 MSEK

2025-08-29 14:00:00 PILA PHARMA: H1 REPORT INTERVIEW RECORDING WITH DIREKT STUDIOS - CEO COMMENTS ON HEAVILY OVERSUBSCRIBED RIGHTS ISSUE AND PLANS 2,03 SEK | +2,22% | 0,45 MSEK

2025-08-29 13:30:00 PILA PHARMA: CEO VISITS INVESTMENT PODCAST 10X TO COMMENT ON HEAVILY OVERSUBSCRIBED ISSUE (293,5%) AND OBESITY PLANS 2,03 SEK | +2,22% | 0,45 MSEK

2025-08-27 08:00:00 PILA PHARMA PUBLISHES INTERIM REPORT (1 JANUARY - 30 JUNE 2025) 2,00 SEK | -4,31% | 0,41 MSEK

2025-08-21 15:55:00 PILA PHARMA: INVITATION TO LIVE H1 REPORT INTERVIEW AND Q&A 2,24 SEK | -5,49% | 0,28 MSEK

2025-08-21 15:30:00 PILA PHARMA ANNOUNCES THE COMPLETION OF REGISTRATION OF SHARES IN THE RIGHTS ISSUE AND ITS ASSOCIATED DIRECTED ISSUES, MARKING THE END OF THE RIGHTS ISSUE PROCESS 2,24 SEK | -5,49% | 0,28 MSEK

2025-07-31 15:30:00 PILA PHARMA announces updated dates for last day of trading with paid subscribed units and first day of trading in new shares 3,05 SEK | -8,82% | 0,13 MSEK

2025-07-23 08:55:00 The board of directors of PILA PHARMA has resolved to carry out a directed issue of units to underwriters in the previously ended rights issue 3,48 SEK | -0,71% | 0,21 MSEK

2025-07-21 13:45:00 PILA PHARMA announces the outcome of its oversubscribed rights issue and resolves on a directed issue for over-allotment 3,44 SEK | +2,23% | 0,44 MSEK

2025-07-14 13:20:00 THE LAST DAY OF SUBSCRIPTION OF UNITS IN PILA PHARMA'S RIGHTS ISSUE OF UNITS 3,76 SEK | +13,08% | 0,63 MSEK

2025-07-10 10:20:00 THE LAST DAY OF TRADING IN UNIT RIGHTS IN PILA PHARMA'S RIGHTS ISSUE OF UNITS 3,20 SEK | -15,57% | 0,39 MSEK

2025-07-09 09:25:32 PILA PHARMA: INVESTMENT PODCAST GÖTT TJÖT OM AKTIER INTERVIEWS CEO ABOUT RIGHTS ISSUE AND OBESITY ASPIRATIONS 3,79 SEK | +1,34% | 0,82 MSEK

2025-07-08 09:16:32 PILA PHARMA: FINWIRE SIT-DOWN INTERVIEW TALKING FUNDRAISING AND BET ON OBESITY 3,74 SEK | +31,69% | 0,76 MSEK

2025-07-07 11:30:00 PILA PHARMA: NEW INTERVIEW ON RIGHTS ISSUE AND BET ON OBESITY WITH DIREKT STUDIOS 2,84 SEK | +3,84% | 0,29 MSEK

2025-07-04 14:00:00 CEO DISCUSSES ONGOING RIGHTS ISSUE AND BET ON OBESITY WITH INVESTMENT PODCAST 10X 2,73 SEK | +8,32% | 0,18 MSEK

2025-07-01 10:41:00 The subscription period in PILA PHARMA's rights issue of units begins today 2,65 SEK | +1,73% | 0,12 MSEK

2025-07-01 09:05:00 PILA PHARMA DISCUSSES ITS FINANCING ROUND WITH HELGE LARSEN & PROINVESTOR 2,65 SEK | +1,73% | 0,12 MSEK

2025-06-25 13:30:00 THE LAST DAY OF TRADING IN PILA PHARMA'S SHARES INCLUDING THE RIGHT TO RECEIVE UNIT RIGHTS 2,98 SEK | -5,38% | 0,10 MSEK

2025-06-25 13:00:00 PILA PHARMA PUBLISHES PROSPECTUS IN CONNECTION WITH THE ANNOUNCED RIGHTS ISSUE OF UNITS 2,98 SEK | -5,38% | 0,10 MSEK

2025-06-19 15:20:00 THE BOARD OF DIRECTORS OF PILA PHARMA HAS RESOLVED TO CARRY OUT A RIGHTS ISSUE OF UNITS OF APPROXIMATELY SEK 20 MILLION 3,07 SEK | +4,39% | 0,05 MSEK

2025-06-18 13:48:36 PILA PHARMA: ALL INVESTOR PRESENTATION RECORDINGS NOW ONLINE 2,94 SEK | -7,95% | 0,06 MSEK

2025-06-17 14:48:42 PILA PHARMA VISITED DIREKT STUDIOS' INVESTMENT CHANNEL 3,20 SEK | -2,98% | 0,13 MSEK

2025-06-16 15:53:18 PILA PHARMA PARTICIPATED IN INVESTMENT PODCAST 10X 3,30 SEK | +5,72% | 0,22 MSEK

2025-06-10 17:00:00 PILA PHARMA INVITES TO AFTER-WORK MINGLE IN STOCKHOLM 2,65 SEK | -0,83% | 0,32 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Pila Pharma

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden